Ascendis Pharma A/S (ASND) Stock Overview
Explore Ascendis Pharma A/S’s financial performance, market position, analyst ratings, and future outlook.
Ascendis Pharma A/S (ASND)
Key Financials
Key Financials
Market Cap
15.7B
P/E Ratio
18.10
EPS (TTM)
$-2.42
ROE
1.90%
ASND Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Ascendis Pharma A/S (NASDAQ: ASND) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Ascendis Pharma A/S's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ASND on the NASDAQ shows an RSI of 54.16, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $218.70 for the NASDAQ listing.
Key metrics behind Ascendis Pharma A/S's NASDAQ-traded stock include a P/E ratio of 18.10 and a market capitalization of 15.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ASND on the NASDAQ.